Pharmacokinetics of BID versus QID Dosing of Sulfadiazine in HIV-infected Patien

本研究是一项开放标签、随机交叉研究，旨在比较磺胺嘧啶每日两次给药与每日四次给药的药代动力学。将入组10名CD4计数低于500的HIV感染患者。患者不得并发机会性感染，并且必须愿意遵守研究方案。本研究旨在比较两种剂量（1000 mg QID和2000 mg BID）的磺胺嘧啶药代动力学参数和血清浓度。此外，本研究将评估这些给药方案的安全性和耐受性。目前，该研究已获得研究所审查委员会的批准，并将在未来1至2个月内开始入组。

This study is an open-label, randomized crossover study to compare the pharmacokinetics of sulfadiazine given on a twice-daily basis with a four-times-daily schedule. Ten HIV-infected patients with CD4 counts below 500 will be enrolled. Patients must not have concurrent opportunistic infections and must be willing to comply with the study regimen. The study is designed to compare pharmacokinetic parameters and serum concentrations of sulfadiazine at two doses: 1000mg QID and 2000mg BID. Additionally, this study will assess the safety and tolerability of these dosage regimens. Currently, the study has received Institute Review Board approval and will begin enrolling within the next 1 to 2 months.